Antimicrobial resistance is projected to kill up to 10 million people a year by 2050. We won’t let this happen.
TAXIS Pharmaceuticals is developing therapies to combat antimicrobial resistance addressing the root cause of the issue, targeting the very foundation of bacterial survival. Our approach goes beyond traditional methods – we’re dismantling the cellular infrastructure, breaking down barriers, and disrupting the mechanisms that fuel antimicrobial resistance.
At TAXIS Pharmaceuticals, we envision a world where antimicrobial resistance is a thing of the past.
Our Investigational Therapeutics
Read our latest news and insights
Joe DePinto, MBA and Frank Carlo Pasqualone, MBA Named to Board of Directors
TAXIS Pharmaceuticals has named two industry professionals with extensive biopharma experience, Joeseph DePinto, MBA, and Frank Carlo Pasqualone, MBA, to its Board of Directors.
Smart Investing in Antimicrobial Resistance Solutions Disrupts Biotech Market
Antimicrobial resistance (AMR) has quickly become one of the most pressing health and economic challenges of our time, and it's creating an inflection point for biotech innovation and investment. With at least 1.27 million deaths attributed to AMR annually, the cost of inaction is clear. Beyond a moral obligation, investment in AMR is also a smart economic decision, and investors have begun disrupting the biotech market by supporting the momentum of the novel AMR solution pipeline.
Contagion Live: A Group of Antimicrobial Compounds Shows Novelty Action Against Multidrug-Resistant Gonorrhea
TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae, a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae.